Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 16/20 | 0.68 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.61 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL9060786 | 0.91 | HCAR3 (0.63) | HCAR3PTK2HCAR2 | |
| Pyridine SCHEMBL5437479 | 0.91 | HCAR3 (0.59) | HCAR3PTK2HCAR2CYP1A2KMT2A | |
| SCHEMBL7093993 | 0.87 | PTK2 (0.62) | HCAR3PTK2CYP1A2GAAKMT2A | |
| SCHEMBL27343709 | 0.87 | KDM4E (0.62) | HCAR3PTK2HCAR2KMT2A | |
| SCHEMBL28118455 | 0.86 | PTK2 (0.54) | HCAR3PTK2CYP1A2GAAKMT2A | |
| SCHEMBL27347169 | 0.85 | HCAR3 (0.55) | HCAR3PTK2HCAR2CYP1A2GAA | |
| SCHEMBL27349315 | 0.84 | HCAR3 (0.50) | HCAR3PTK2HCAR2KMT2A | |
| SCHEMBL27347795 | 0.84 | HCAR3 (0.52) | HCAR3PTK2HCAR2GAAKMT2A | |
| SCHEMBL27335268 | 0.84 | HCAR3 (0.52) | HCAR3PTK2HCAR2KMT2A | |
| SCHEMBL25190504 | 0.84 | PTK2 (0.59) | HCAR3PTK2CYP1A2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819333-A | Preparation method of Abelix intermediate 6-aminonicotinic acid | 浙江科聚生物医药有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190175567-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-06-13 | — | — | US | disclosed |
| WO-2018086703-A1 | DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-9844539-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9844539-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-6835724-B2 | Topical antiinflammatory agents for treating inflammatory dermatoses | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-28 | — | — | US | disclosed |
| WO-2004029055-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040014766-A1 | Amide substituted xanthine derivatives | HOFFMANN-LA ROCHE INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003106459-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | disclosed |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-01 | — | — | US | disclosed |
| US-5608093-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0646593-A1 | Corticoid-17,21-dicarboxylic acid ester and corticosteroid-17-carboxylic acid ester-21-carbonic, process for their production and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0640616-A2 | 17-Alkylcarbonate, 21-0-carbonic/carboxylic acid esters of corticosteroids, a method for their production and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
| EP-0244728-B1 | USE OF HETEROARYLETHYL AMINES TO STIMULATE ANIMAL GROWTH, HETEROARYLETHYL AMINES AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0244728-A2 | Use of heteroarylethyl amines to stimulate animal growth, heteroarylethyl amines and process for their preparation | BAYER AG (DE) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014766-A1 | Amide substituted xanthine derivatives | GYS2, GLS2, PYGL | HCAR3 679/4885PTK2 4679/4885HCAR2 833/4885 |
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HCAR3 3320/4885PTK2 118/4885HCAR2 3241/4885 |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | NR3C1, HSD3B1, HSD17B7 | HCAR3 57/4885PTK2 1888/4885HCAR2 58/4885 |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HCAR3 3320/4885PTK2 118/4885HCAR2 3241/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HCAR3 2703/4885PTK2 4052/4885HCAR2 1991/4885 |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, MAP3K13, MAP3K8 | HCAR3 3320/4885PTK2 118/4885HCAR2 3241/4885 |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HCAR3 3320/4885PTK2 118/4885HCAR2 3241/4885 |
| US-20190175567-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HCAR3 3320/4885PTK2 118/4885HCAR2 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.